TCM
KURA icon

TCG Crossover Management’s Kura Oncology KURA Stock Holding History

TCG Crossover Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-735,184
Closed -$4.24M – 45
2025
Q2 		$4.24M Sell
735,184
-688,458
-48% -$4.22M 0.48% 31
2025
Q1 		$9.4M Hold
1,423,642
– – 1.28% 25
2024
Q4 		$12.4M Hold
1,423,642
– – 1.21% 27
2024
Q3 		$27.8M Hold
1,423,642
– – 2.36% 18
2024
Q2 		$29.3M Hold
1,423,642
– – 3.06% 13
2024
Q1 		$30.4M Hold
1,423,642
– – 2.4% 19
2023
Q4 		$20.5M Hold
1,423,642
– – 2.27% 19
2023
Q3 		$13M Hold
1,423,642
– – 1.91% 20
2023
Q2 		$15.1M Hold
1,423,642
– – 2.47% 12
2023
Q1 		$17.4M Hold
1,423,642
– – 3.39% 12
2022
Q4 		$17.7M Buy
1,423,642
+75,000
+6% +$1.09M 3.12% 13
2022
Q3 		$18.4M Buy
1,348,642
+181,000
+16% +$2.79M 5.53% 7
2022
Q2 		$21.4M Buy
1,167,642
+661,219
+131% +$9.51M 9.09% 4
2022
Q1 		$8.14M Buy
+506,423
New +$7.31M 3.27% 12

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

TCG Crossover Management's KURA Position: Q3 2025 in Review

TCG Crossover Management sold out of Kura Oncology (KURA) in Q3 2025, closing a stake of 735,184 shares — an estimated $4.24M sold.

TCG Crossover Management first reported a position in KURA in Q1 2022 and held it in 14 quarters. The position peaked at $30.4M in Q1 2024. 200 funds tracked by Wall St. Rank hold KURA as of Q3 2025.

  • TCG Crossover Management reported no remaining Kura Oncology position as of Q3 2025 after selling out during the quarter.
  • TCG Crossover Management sold 735,184 Kura Oncology shares in Q3 2025, an estimated $4.24M.
  • TCG Crossover Management first reported a position in Kura Oncology in Q1 2022 and held it in 14 quarters.
  • TCG Crossover Management's Kura Oncology position peaked at $30.4M in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2025.

Based on TCG Crossover Management's 13F filing for Q3 2025, filed 17 Nov 2025.